Business Wire

Novaliq GmbH Appoints Friedrich von Bohlen, PhD, as Chairman and Gerald Cagle, PhD, as New Member of Novaliq’s Supervisory Board

Del

Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that Friedrich von Bohlen, PhD, has been appointed Chairman of the company’s Supervisory Board and that Jerry Cagle, PhD, has joined the Board as Member.

Dr. von Bohlen has been active in the Life Sciences since 1997 and brings 20 years of entrepreneurial experience to his position. In 2005, Dr. von Bohlen co-founded dievini Hopp BioTech holding GmbH & Co KG. where he holds the position of Managing Director. Furthermore, he serves as chairman or board member of several supervisory boards that are part of the dievini portfolio. Dr. von Bohlen began his professional career in 1992 serving as a project manager in research & development at Fresenius AG. He then served as assistant to the chairman of the supervisory board of FAG Kugelfischer KGaA, and thereafter as CEO of Wasag Chemie AG. In 1997 he co-founded Lion Bioscience AG where he served as CEO until 2004 when he was named Chairman of the Board. Dr. von Bohlen holds a Diploma in Biochemistry from the University of Zurich and a PhD in Neurobiology from the Swiss Federal Institute of Technology.

Dr. Cagle began his career as an academic, serving as a faculty member of The Ohio State University in Columbus. Thereafter, and for more than three decades, he worked as a member of Alcon’s research and development team. In 1996, Dr. Cagle was named Senior Vice President of Alcon R&D and Chief Scientific Officer, a position he held until mid-2008. As head of Alcon R&D, he led the global activities of some 1,300 scientists stationed around the world. The productivity of the R&D organization, and the new products introduced during his tenure, has been recognized as a primary contributor to Alcon’s significant growth. Following his departure from Alcon, he worked on the management of Alzheimer's disease. He serves on the Board of Aerie Pharmaceuticals, Clearside Biomedical, AB2, and GrayBug. Dr. Cagle received his B.S. degree from Wayland College in Plainview, Texas, and earned both his MS and PhD degrees from the University of North Texas in Denton, Texas.

“We are pleased to have Friedrich join Novaliq as the chairman of our supervisory board. His 20 years of entrepreneurial experience is of great importance for the further prosperity of the company and especially in building a successful specialty pharma company focusing on ophthalmology,” said Mr. Günther, Novaliq’s CEO and Managing Director.

“We are delighted to have Jerry join our supervisory board. His long-term experience and vast ophthalmic knowledge is a great win for Novaliq and important for future company growth,” said Dr. Schlüter, Novaliq’s CFO and Managing Director.

“Jerry’s broad business and R&D background in this industry is an important contribution and will be crucial for Novaliq with regard to the evaluation and development of highly effective ocular therapeutics,” said Dr. von Bohlen, Chairman of Novaliq’s Supervisory Board.

“I’m excited about my new assignment as supervisory board member and look forward to being a part of Novaliq’s further development and growth. With the recent European market launch of EvoTears®, Novaliq has made a significant contribution and step forward in the treatment of dry eye disease,” said Dr. Cagle.

About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical and drug delivery company with the mission to transform poorly soluble drugs into effective ocular therapeutics for both front and back of the eye. Novaliq’s proprietary technology enhances the topical bio availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq’s most advanced product is EvoTears® with CE-marking based on Novaliq’s proprietary EyeSol® Technology. More on www.novaliq.com.

Contact information

Europe
Novaliq GmbH
Bernhard Günther, + 49 6221 502 5911
Managing Director, CEO
info@novaliq.de
or
USA
Scotia Vision Consultants
Michael O’Rourke, + 1 813-323-1438
scotiavc@gmail.com
or
Novaliq GmbH
Oliver Schlüter, PhD, + 49 6221 502 59155
Managing Director, CFO
info@novaliq.de

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Edgewater Networks Announces Event Sponsorship of BroadSoft Connections 201720.10.2017 21:00Pressemelding

Edgewater Networks, Inc., the industry leader in Network Edge Orchestration, announced today that it is an event sponsor of the BroadSoft Connections 2017 user conference, which takes place October 22-25 at the JW Marriott Phoenix Desert Ridge Resort & Spa in Phoenix, AZ. During the event, Edgewater Networks will feature demonstrations of the latest end-to-end network interoperability capabilities, including Zero Touch Provisioning, UC Analytics from the core to the endpoint, SD-WAN optimized for BroadSoft, and much more. Continuing a long-standing partnership with BroadSoft, Edgewater Networks has completed another level of BroadCloud certification, this time for local survivability which is critical for business continuity for SMB and Enterprise customers. BroadSoft’s PacketSmart is available on all EdgeMarc Intelligent Edges. All elements of the Network Edge Orchestration are

More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08Pressemelding

The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable

Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15Pressemelding

Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside

Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03Pressemelding

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f

SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47Pressemelding

SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171020005325/en/ Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom